ID   MOLP-5
AC   CVCL_5842
SY   MOLP5
DR   CGH-DB; 34-1
DR   CGH-DB; 9147-4
DR   Wikidata; Q54906337
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=10848782;
RX   PubMed=10936422;
RX   PubMed=15215163;
CC   Population: Japanese.
CC   Characteristics: Produces Ig kappa.
CC   Doubling time: ~48 hours (PubMed=10848782).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_L601 ! B407
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 14
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=10848782; DOI=10.1046/j.1365-2141.2000.01985.x;
RA   Matsuo Y., Drexler H.G., Nishizaki C., Harashima A., Fukuda S.,
RA   Kozuka T., Sezaki T., Orita K.;
RT   "Human bone marrow stroma-dependent cell line MOLP-5 derived from a
RT   patient in leukaemic phase of multiple myeloma.";
RL   Br. J. Haematol. 109:54-63(2000).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//